Bills: S3082, S3090, H5425, H5130, H5114

Keywords: animal telehealth, veterinary telemedicine, veterinary telehealth, veterinarian-client-patient relationship, VCPR, animal health, pet care, companion animal, livestock, remote veterinary care, synchronous audio-video, telemedicine, prescription drugs, antimicrobial drugs, controlled substances, xylazine, compounding pharmacy, veterinary practice, Massachusetts Controlled Substances Act, animal owner

Summary: The Joint Committee on Consumer Protection and Professional Licensure held a hearing on late-filed bills, with testimony heard both in person and remotely. The committee reviewed several measures, including H. 355 and S. 3082 on veterinary telemedicine/telehealth, H. 5445 on additional liquor licenses for East Hampton, and S. 3090/H. 5114 on consumer-connected devices and software support disclosure. The chair outlined hearing logistics, including three-minute testimony limits and written testimony submission, and noted that Lawrence High School students were present to observe. On the veterinary bills, supporters of H. 355 argued that allowing veterinarians to establish a client-patient relationship remotely would improve access to care for pets whose owners face transportation, mobility, or anxiety-related barriers, and could help veterinarians continue practicing through telemedicine. Opponents of S. 3082, including the Massachusetts Veterinary Medical Association and several veterinarians, said the initial in-person exam is essential to detect conditions that cannot be seen on video, avoid misdiagnosis, and preserve the standard of care; they emphasized that teletriage and follow-up telemedicine are already used after an in-person relationship is established. Committee members pressed both sides on the distinction between teletriage and establishing the relationship, the timing of annual exams, and whether limited exceptions for sedatives or other pre-visit needs might be workable. Senator Lovely testified in support, citing a recent Lyme case where follow-up telemedicine would have been useful. On H. 5445, Representative Gomez and East Hampton Mayor Salem Derby urged approval of the bill to authorize eight additional liquor licenses, saying the city has reached its current cap, needs economic development, and wants to support downtown revitalization and new restaurant growth. Members asked about public safety and the number of licenses sought; the mayor said local public safety officials support the request and that the licenses would be for restaurants, not bars. On S. 3090 and H. 5114, consumer advocates and cybersecurity experts supported requiring manufacturers of connected devices to disclose software support timelines, arguing it would improve consumer transparency, cybersecurity, and reduce e-waste. Industry groups opposed the bills, saying fixed disclosure requirements could be impractical, create confusion, burden small businesses, conflict with federal efforts, and be difficult to apply to appliances, lighting, and other products with long lifecycles. The committee did not take a substantive vote on the bills during the hearing; at the end, staff announced a forthcoming poll for House members, and the committee voted to adjourn.

Bills: S3082, S3090, H5425, H5130, H5114

Keywords: animal telehealth, veterinary telemedicine, veterinary telehealth, veterinarian-client-patient relationship, VCPR, animal health, pet care, companion animal, livestock, remote veterinary care, synchronous audio-video, telemedicine, prescription drugs, antimicrobial drugs, controlled substances, xylazine, compounding pharmacy, veterinary practice, Massachusetts Controlled Substances Act, animal owner

Transcript Highlights:

• To contrast xylazine as a drug supply contaminant, we heard from our friends at DPH that the xylazine
• It's worth repeating that people who are utilizing, who are using xylazine and exposed to xylazine, Who
• and people exposed to xylazine.
• Exposed xylazine contamination.
• A lack of education about xylazine and awareness of xylazine can perpetuate stigma, which really can

Keywords: 995, all

Summary: The special commission on xylazine met virtually to review and discuss the first draft of its final report. Chair Mindy Domb opened the meeting, confirmed quorum, and the commission approved the minutes from its December 11 public meeting. Staff then walked commissioners through the proposed report structure, including background on xylazine as both an FDA-approved veterinary drug and an illicit drug supply contaminant, as well as appendices for public meeting materials and public resources. The commission discussed findings and recommendations for several working groups. For oversight and enforcement, members focused on licit versus illicit sources of xylazine, noting that the illicit supply is typically obtained through online vendors rather than diverted from veterinary use. Recommendations included better storage and reporting practices in authorized settings, review of manufacturing and distribution information, and focusing enforcement on fentanyl trafficking and large-scale xylazine importation rather than personal possession. Commissioners also discussed whether xylazine should remain in Schedule 6 or be subject to additional penalties, and several members emphasized the need for coordination, information-sharing, and possibly a DPH task force or advisory body to monitor emerging drug threats. For outreach and treatment, staff summarized strong existing programs such as drug checking, wound care education, naloxone distribution, mobile and low-threshold care, and self-directed wound kits, while noting gaps including the lack of an FDA-approved reversal agent for xylazine, difficulty distinguishing xylazine from other exposures, and uneven access by geography, insurance, and audience. Commissioners stressed the need for provider education, including physicians, nurses, pharmacists, family support networks, and first responders, and for clear guidance on wound care and when more intensive treatment is needed. The education and training section identified first responders, clinicians, non-clinicians, and people who use drugs and their families as key audiences for tailored, stigma-free materials, with emphasis on real-time, centralized data, naloxone and breathing support, recognition of overdose versus xylazine exposure, and adapting materials as the drug supply changes. The meeting ended with discussion of next steps: staff will circulate a revised draft by March 2, the commission will meet again on March 9 to consider the report and recommendations, and an additional late-March meeting was reserved if needed before the statutory deadline.

Transcript Highlights:

• in the opioid overdose toxicology, DPH's actions related to xylazine, our CDC and xylazine recommendations
• Xylazine is a problem.
• xylazine-associated overdoses.
• Between 24 and 48 hours after exposure to xylazine and the types of effects of xylazine exposure.
• So their drug samples indicated that they had used xylazine or been exposed to xylazine.

Keywords: 995, all

Summary: The Special Commission on xylazine held its first meeting, with House Chair Mindy Domb and Senate Co-Chair John Keenan outlining the commission’s charge and a proposed work plan. The commission is tasked with studying the public health and safety impacts of xylazine in the illicit drug supply, including whether it should be scheduled as a controlled substance, how to regulate its production and distribution, and how to improve outreach and treatment for people exposed to it. Members were told the report deadline had been extended to March 30, 2026, and staff proposed a series of public hearings and working groups leading to a final report. The meeting also included attendance, packet materials, and procedural planning. The first major testimony came from BSAS Director Deirdre Calvert, who described xylazine’s appearance in Massachusetts drug supply data, the state’s public health alerts, and DPH’s partnership with Brandeis, CDC, and harm reduction organizations. She emphasized four priorities: reducing stigma and discrimination in health care, expanding self-directed wound care support and coverage for supplies, expanding access to drug checking and test strips, and supporting low-barrier services such as mobile vans and drop-in centers. Commission members asked about first responder awareness, medical education, and whether harm reduction services might face federal restrictions; Calvert said misinformation remains a problem and noted ongoing training efforts, including collaboration with public safety agencies. Several other speakers reinforced the need for low-barrier care and drug checking. Dr. Raghini Jala, an infectious disease and addiction medicine physician, said xylazine has become a common component of the unregulated opioid supply and urged support for rapid-response education teams, community-based drug checking, and better hospital and detox protocols for xylazine withdrawal and wounds. Recovery coach Alan Young testified from lived experience, describing severe wounds, fear of inadequate withdrawal treatment in emergency settings, and the value of mobile care vans that can provide methadone, buprenorphine, and wound care in the community. Dr. Sarah Wakeman echoed the need for naloxone, rescue breathing, low-threshold treatment, and non-stigmatizing health care settings, while Sarah Macon of the Boston Public Health Commission described Boston’s harm reduction and drug checking work, including on-site testing, wound care, and a decline in opioid mortality. Tracy Green of the Massachusetts Drug Supply Data Stream explained that xylazine has declined in recent samples while metatomidine is rising, said drug checking is increasingly used but still not enough, and argued for more funding, staffing, and statewide access to real-time drug checking and harm reduction services.

Transcript Highlights:

• And I'm going to share an article that she sent me about xylazine.
• xylazine.
• , only for xylazine, that's the benefit.
• So I can imagine what xylazine is with fentanyl. Where is it... And what xylazine is with fentanyl.
• But there are similar chemical compounds, you know, to xylazine.

Keywords: 995, all

Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.

Transcript Highlights:

• itself and the pH of xylazine.
• But in the middle were xylazine test strips.
• Right now, we're seeing mitigation of xylazine.
• And that's going to land xylazine right back in.
• To be honest, I even went to my dermatologist and they had no idea what xylazine was or what xylazine

Keywords: 995, all

Summary: The Special Commission on Xylazine convened its second meeting, approved the minutes from its June 23 meeting, and reviewed its timeline and working groups. The co-chairs said the commission’s final report is due to the House and Senate clerks by March 30, 2026, and outlined three working groups focused on regulation/oversight of xylazine, treatment and outreach for exposed patients, and education/training for first responders, clinicians, treatment providers, and people who use substances. Staff will schedule working group meetings, with group presentations planned for December 11, followed by commission meetings in February and March to review and finalize the draft report. Public comment centered on research and practical responses to xylazine contamination in the drug supply. Dr. Tracy Green of Brandeis reviewed recent studies showing severe xylazine-related wounds and amputations in Philadelphia, withdrawal symptoms, the value of wound identification tools, and the usefulness of drug checking in detecting xylazine even when users did not suspect it was present. She urged expanded low-barrier wound care, more access to medications for opioid use disorder, overdose prevention sites, housing, and trauma-informed care, while cautioning that stricter controls could push the market toward other dangerous alpha-2 substances. Commissioners asked about early wound identification, dilution/cutting strategies, supplier engagement, and how to reduce stigma and improve treatment access. Tia Johnson of Boston Medical Center and Boston Health Care for the Homeless testified that xylazine contamination still requires naloxone for overdose response, but sedation can last longer and may require low-dose naloxone, oxygen support, and low-threshold monitoring spaces. She emphasized that xylazine-associated wounds can heal with consistent care, but patients often lose access to services when sent to hospitals unnecessarily. Commissioners discussed reimbursement barriers, especially in MassHealth and behavioral health settings, and the need for wound care to be available within detox and treatment programs rather than requiring transfers. The meeting ended with agreement to continue working group planning and adjournment.

Transcript Highlights:

• There's a lot of knowledge about xylazine, and I think there's a lot less knowledge about xylazine elsewhere
• You know, in addition to xylazine, there's more knowledge about xylazine, but there's less knowledge
• So I think exposure to xylazine complicates withdrawal management for patients.
• You know, we're talking about xylazine right now.
• It won't just be on xylazine.

Keywords: 995, all

Summary: The Working Group on Outreach and Treatment of the Special Commission on Xylazine held its first meeting, chaired by Gabe Adams-Cain in Senator John Villis’s absence. Members introduced themselves and described priorities such as improving education about xylazine, expanding first responder and clinical training, and ensuring patients and providers know how to respond to xylazine-related wounds and complications. Several participants emphasized that outreach should reach both people who have not been exposed and those already affected, and that stigma is a major barrier for patients and families. Discussion focused on the main challenges to treatment and outreach, including limited awareness, inconsistent wound care access, gaps in geographic coverage, cost of supplies, and the need for better training in both outpatient and inpatient settings. Dr. Kimmel noted that harm reduction and outreach programs are already providing much of the care, but often lack specialized staff, sufficient supplies, and standardized protocols. He also said xylazine can complicate withdrawal and make it harder for people to engage in substance use treatment. Members discussed the value of non-stigmatizing, consensus messaging, family support organizations, and existing resources such as PARI, StreetCheck, and state-funded syringe service and naloxone networks. The group also reviewed the commission timeline and next steps. Staff said materials for the December 11 full commission meeting should be submitted by December 2, with draft presentation materials to be shared by December 4 and reviewed by December 9. Members agreed to do additional follow-up research on topics including the cost-effectiveness and contents of self-care wound kits, outreach to family and recovery organizations, incarcerated populations, and geographic access gaps. The meeting ended with agreement to use a PowerPoint-style presentation and to continue compiling research through a shared folder, followed by adjournment at 9:55 a.m.

Transcript Highlights:

• first meeting of the Working Group on Education and Training, convened by the Special Commission on Xylazine
• Would that be effective when you see someone exposed to xylazine?
• You will be able to: one, describe xylazine and its harms; two, describe signs of xylazine poisoning
• What is xylazine? What essential knowledge should, you know, members of each population have?
• Xylazine, what essential knowledge should, you know, members of each population have?

Keywords: 995, all

Summary: The Working Group on Education and Training of the Special Commission on Xylazine held its first meeting to begin developing findings and recommendations on education and training for first responders, the medical community, the substance use treatment community, and people who use drugs. Members discussed the need for baseline information on what xylazine is, its clinical effects and harms, signs of exposure or poisoning, wound care, and immediate response steps, while also noting that training should be tailored by audience, geography, and role. Several members emphasized that the training should be practical and action-oriented, helping people recognize xylazine exposure and know what to do next, including whether naloxone is relevant and how to reduce risk and mitigate harm. A major theme was whether the group should recommend a needs assessment or survey to identify what different audiences already know and what they still need to learn. Members suggested that BSAS, DPH, local public health departments, licensing boards, and other stakeholders could help gather this information, and that existing resources such as DPH materials, MADS data, Brandeis materials, and trainings already being funded at BMC should be reviewed. The group also discussed the importance of using plain language for non-clinical audiences while still including clinical detail for providers, and of distinguishing between clinical and non-clinical training tracks. The working group agreed to divide into subgroups: Senator Keenan will focus on first responders, Dr. Simon on the medical community, and Millie Batiya on the substance use treatment community, while Chair Domb will focus on people who use drugs. Staff will send meeting notes, an early draft PowerPoint framework, and a shared Google Drive folder for materials. Members were asked to gather sources and ideas by November 25 ahead of the December 11 public meeting. The meeting ended with a motion to adjourn, a second, and unanimous thanks to staff and participants.

Transcript Highlights:

• , the state and federal actions to address xylazine.
• Xylazine is an expensive, easy-to-obtain illicit material that distributors seek, and adds xylazine as
• Xylazine is an expensive, easy-to-obtain illicit material that distributors seek, and adds xylazine as
• On how to approach xylazine-related cases.
• Xylazine, I want to continue to work with the compliance.

Keywords: 995, all

Summary: The Special Commission on the Public Health Effects of Xylazine held its fifth and final public meeting to review and approve the final draft of its report before submission to the House and Senate clerks. Chair Mindy Domb opened the meeting, noted Senator John Keenan’s absence due to National Guard deployment, approved the prior meeting minutes, and explained the process for incorporating final edits and late votes into appendices. Commissioners then voted to allow staff to make agreed-upon language changes after the meeting, and later voted on the final report itself. Staff walked commissioners through the report’s redlines and substantive updates. Changes included clarifying that xylazine is an active adulterant rather than simply a bulking agent, replacing “non-clinician” with “non-clinical staff,” removing or revising references to “hotspots” in favor of more accurate language about local trends, and refining language on wound care to refer to medical consequences and financial costs. The report also added or strengthened discussion of harm reduction measures such as drug checking, mobile health services, overdose prevention centers, oxygenation and airway support during overdose response, and the importance of naloxone remaining available while recognizing its limits for xylazine exposure. Commissioners also discussed data collection, legal protections for drug checking, and the role of the Attorney General in guidance and coordination on emerging drug threats. The commission then took a final vote, with the members present voting to approve the report. A letter from Senator Velis, who was also absent due to active duty orders, was read into the record expressing support for the report and its recommendations. In closing comments, commissioners and staff thanked one another for the collaborative work and described the report as a useful public health resource. Chair Domb adjourned the meeting at 11:11 a.m., noting that the final report would be submitted and posted online for public access.

Transcript Highlights:

• Xylazine is a veterinary drug.
• Xylazine is a veterinary drug.
• Xylazine is a veterinary drug.
• Xylazine is a veterinary drug.
• of xylazine positive toxicology. of xylazine positive toxicology.

Keywords: 1191, senate, all

Transcript Highlights:

• , but it's important to note that xylazine is a national issue.
• And second, the bill creates a new offense for trafficking in xylazine.
• And second, the bill creates a new offense for trafficking in xylazine.
• Xylazine, also known as Trank, is a drug used by veterinarians.
• People who inject drug mixtures containing xylazine can also develop...

Summary: The Criminal Justice Subcommittee heard and advanced a series of bills on inmate medical billing, court-order transmission, animal abandonment during disasters, first responder peer support, firearm purchase waiting periods, capital felony aggravators, domestic violence protections, boating safety, restitution for leaving the scene of a crash, xylazine trafficking, and offenses against law enforcement officers. Testimony was generally supportive across the agenda, with some opposition or caution raised on the xylazine bill, the boating safety bill, and parts of the law-enforcement-officer bill. Several measures were presented as responses to specific tragedies, including the Martin County jail medical billing bill, the Baker Act transmission bill, Trooper’s Law for restrained dogs, the Jason Rayner Act, and Lucy’s Law. HB 407 would cap certain emergency medical charges for Martin County jail inmates at 110% of Medicare rates, mirroring Department of Corrections practice; it passed 15-0. HB 513 would require faster electronic transmission of certain court orders, including Baker Act orders, to law enforcement within six hours; it passed 15-0. HB 205, Trooper’s Law, creates a third-degree felony for abandoning a restrained dog during a natural disaster; it passed 15-0. HB 421, as amended, expands peer support for first responders to certain support personnel involved in crime scene work or evidence handling; it passed 16-0. PCS for HB 383 would let law enforcement, correctional officers, correctional probation officers, and active military service members bypass the three-day handgun waiting period without a concealed carry permit; it passed 18-0. HB 693 adds an aggravating factor in capital cases when the victim was gathered with others for a school, religious, or public government meeting; it passed 17-1 after opposition testimony from Floridians for Alternatives to the Death Penalty. PCS for HB 19 and HB 41, the Haven Act, would expand domestic and dating violence protections, including a feasibility study for a web-based 911 alert system and confidentiality/public-records protections for victims; both passed 18-0. PCS for HB 289, Lucy’s Law, would align boating penalties with driving offenses and expand boating safety card requirements; it passed 18-0 despite concerns from one witness that the bill should go further. HB 479 would allow courts to order restitution in leaving-the-scene property-damage cases; an amendment changing mandatory to discretionary restitution was adopted, and the bill passed 18-0. PCS for HB 57 would regulate xylazine, add trafficking penalties, and include veterinary-use exceptions; it passed 17-0 after one witness opposed mandatory minimums. HB 175, the Jason Rayner Act, clarifies that officers are protected when acting within the scope of their duties and adds manslaughter of a law enforcement officer to offenses requiring life imprisonment; it passed 17-0 after debate over self-defense and unlawful police conduct.

Transcript Highlights:

• Xylazine has tripled the effect of deaths in our region.
• Florida, which added xylazine to Schedule I in 2018, experienced an increase in the prevalence of xylazine
• Xylazine means that I can give the same dose of xylazine to a horse 100 times and achieve the exact same
• With xylazine, that’s not the case.”
• to xylazine.

Summary: The committee heard several public safety bills, with testimony split between supporters who framed the measures as targeted fixes and opponents who warned about overcriminalization and unintended consequences. SB 701, by Senator Wahab, drew support from law enforcement and local government groups, who said state law lacks a tool to address the conduct at issue; the ACLU opposed it as duplicative of existing law, while public defenders said they may withdraw opposition after amendments. Because there was no quorum at that point, the bill was held open without a vote. SB 834, by Senator DeRazzo, was presented as a technical cleanup bill to improve California’s automatic record clearance system by preventing outdated “pending” charges from blocking relief, requiring local court records to match DOJ records, and creating a way for people to obtain proof of relief. It received broad support from criminal justice reform and defense organizations, with no opposition, and the chair indicated support, but no final action was taken during the hearing. SB 248, by Senator Rubio, would require DOJ to send new gun purchasers educational materials during the waiting period about safe storage, suicide prevention, domestic violence, and related resources; supporters called it common-sense education, while one opponent argued the information is already available. The committee voted the bill out on a due-pass motion to Appropriations, but it remained on call pending one additional vote. Senator Rubio’s SB 19, the Safe Schools and Places of Worship Act, would create a new offense for credible threats against schools or houses of worship even when no specific individual is named. Supporters, including law enforcement and Jewish community advocates, said current law leaves a loophole and that the bill would help prevent panic and resource-draining lockdowns; opponents from civil liberties and youth justice groups argued existing law already covers threats and that the bill would worsen the school-to-prison pipeline. After a motion and second, the committee voted due pass to Appropriations, with the measure also left on call. Later, SB 759 by Senator Archuleta, prompted by the killing of Whittier Officer Keith Boyer, would require a court hearing after a third supervision violation or new offense for people on post-release community supervision; supporters said it adds accountability, while opponents said it removes probation discretion and could increase jail and court burdens. The bill passed due pass to Appropriations and was reported as passing. The committee also heard SB 6 by Senator Ashby, which would schedule xylazine as a controlled substance while preserving veterinary use. Supporters, including veterinarians, law enforcement, and a parent who lost a son to a drug-related death, said the drug is increasingly present in fentanyl mixtures and needs to be controlled; opponents from drug policy and civil liberties groups argued scheduling would criminalize users, hinder research, and repeat failed drug-war policies. After extensive debate, the committee voted the bill out due pass to Appropriations, and it passed. Finally, SB 11, the AI Abuse Protection Act, was introduced to regulate AI-generated voice, image, and video replicas, with supporters emphasizing protection against deepfakes and nonconsensual images; the California Chamber of Commerce opposed unless amended, seeking narrower definitions and limits on consumer warnings. The hearing ended while SB 11 was still under discussion, with no final vote reflected in the transcript.

Transcript Highlights:

• Xylazine is a drug used by veterinarians, mostly to sedate or treat large animals.
• Unfortunately, in recent years, xylazine has been showing up more often in drug seizures and toxicology
• , but it's important to note that xylazine is a national problem.
• The bill adds xylazine to the same statute as fentanyl when it resembles a food product or has a cartoon
• character imprint, and the bill creates a new offense for trafficking in xylazine.

Summary: The Justice Budget Subcommittee met with a quorum present and considered two bills. First, the committee heard HB 813 by Rep. Tuck, the state courts’ legislative package, which would require each multi-judge circuit to designate a duty judge for weekends and holidays, repeal the cap on arbitrator compensation in court-ordered non-binding arbitration, and allow an alternative notarization option by a judge. Testimony was waived in support by court-related witnesses, there were no amendments or debate, and the bill passed 14-0. The committee then took up CS for HB 57 by Rep. Plakon, addressing xylazine. The bill adds xylazine to the same statute as fentanyl when packaged to resemble food or marked with cartoon characters, creates a new trafficking offense, and exempts veterinary use. Discussion focused on the bill’s mandatory minimum penalty and its potential fiscal impact on prison beds; Rep. Rainer raised concerns about minimum mandatories and deterrence, while Rep. Daniels said she would support the bill while continuing to work on amendments. Public testimony was waived in support by the Florida Sheriffs Association, the City of Coconut Creek, and the Seminole County Sheriff’s Office. The bill passed 13-1 without amendment. After completing the agenda, the chair noted the meeting had been unusually brief and adjourned the subcommittee.

Transcript Highlights:

• Increase the cost of xylazine? Increase the cost of xylazine?
• stated that the emergence of xylazine stated that the emergence of xylazine across<04:46:49.440>
• xylazine test strips it xylazine<04:47:32.720> and<04:47:32.880> fentanyl<04:47:33.320
• understanding, xylazine has dual understanding, xylazine has dual receptor<04:49:05.880> activity
• So there's a lot of effects of xylazine. So there's a lot of effects of xylazine.

Keywords: 1189, house, all

Transcript Highlights:

• I know you've got an amendment to the bill that I also support around xylazine as well.
• <00:51:42.319> as that I also support around xylazine as that I also support around xylazine
• It's people who have fentanyl together with xylazine.
• And so, I think we need to deal with the xylazine issue in this state.
• And so, I think we need to deal with the xylazine issue in this state.

Keywords: 1189, house, all

Transcript Highlights:

• <00:21:51.200> that strips just fentinal and xylazine that strips just fentinal and xylazine
• Xylazine is a great example.
• Xylazine is a great example.
• Xylazine is a great example. We need us. Xylazine is a great example.
• it turns out it's actually xylazine it turns out it's actually xylazine pressed<00:49:14.720>

Keywords: 1191, senate, all

Transcript Highlights:

• This is the xylazine bill that Representative Plakon carried, and I rode shotgun, and this year we've
• Xylazine, also known as tranq, is a drug used as a tranquilizer for large animals, from horses to elephants
• Number one, it exempts the use of xylazine for veterinary purposes.
• Number two, it creates new criminal offenses relating to xylazine.
• Number two, it creates new criminal offenses relating to xylazine.

Summary: The Justice Budget Committee met with a quorum present and took up four bills. The first, PCS for CS for HB 309 on controlled substances, addressed xylazine (“tranq”), exempting veterinary use and creating criminal offenses related to trafficking and misuse. The sponsor explained changes from the prior version, including removal of a federal-order-related concern and raising the threshold for base possession/trafficking concerns from 4 grams to 28 grams. Public testimony was in support from law enforcement and advocacy groups, and the bill passed 14-0. The committee then heard HB 1467 on penalties for prostitution-related acts. The sponsor said the bill increases penalties for those who solicit, operate prostitution establishments, transport, coerce, or traffic others for prostitution, while not increasing penalties for the people being prostituted. Supporters included Florida Family Voice and the Florida Smart Justice Alliance. The bill passed unanimously, 14-0. Next, CS for HB 1159 on sexual offenses was presented as a broad update to criminal law involving sexual offenses, especially crimes involving minors, child pornography, and sentencing/classification changes. A member asked about a possible Romeo and Juliet issue, and the sponsor said staff was working on clarifying language but did not believe the bill created that problem in its current form. The bill received support from the Florida Sheriffs Association and Florida Smart Justice Alliance and passed 14-0. Finally, CS for HB 485 on petitions for injunction added a checkbox for marriage-fraud allegations in domestic violence injunction petitions, defined marriage fraud for that purpose, and required clerks to notify the State Board of Immigration Enforcement within 24 hours when such an injunction is issued. The sponsor and co-sponsor described it as an accountability measure, it drew support from Florida Smart Justice Alliance, and it also passed unanimously, 14-0. The meeting ended after the chair noted budget recommendations had been submitted and no further business remained.

Transcript Highlights:

• Xylazine is a large animal sedated usually used for surgery.
• externally deep flesh wounds ultimately leading to amputation using what we're seeing right now, Xylazine
• So the people that are using this substance of xylazine or knowing that they're dying his product, but
• Xylazine is said to be in one of 9 of our recent overdose study.
• And I heard you mention that our area is where the xylazine is more prevalent. It's been.

Keywords: 999, senate, all

Transcript Highlights:

• I think no one would argue that xylazine I think no one would argue that xylazine is<03:00:28.640
• <03:03:48.000> And<03:03:48.800> um xylazine bill. And um xylazine bill.
• the frequency that they use xylazine the frequency that they use xylazine now.<03:04:18.920>
• It's always fentanyl plus xylazine.
• them for xylazine as well, too?

Keywords: 1189, house, all

Transcript Highlights:

• Xylazine is a drug used by veterinarians, mostly to sedate or treat large animals.
• Sheriff Lima has actually seen an inmate experiencing necrosis from xylazine.
• It's important to note, though, xylazine is a national issue.
• The bill also creates a new offense for trafficking in xylazine.
• So 200 doses is a lot of xylazine.

Summary: The Judiciary Committee took up a long agenda of 20 bills, beginning with CS/HB 1173 on the Florida Trust Code, which clarified that the Florida Attorney General is the only public official with standing to enforce charitable trusts administered in Florida; it was amended and reported favorably. The committee also unanimously or near-unanimously approved several claims and relief bills, including HB 6507 for Marcus Button, HB 6523 for Darlene Engerville and J.R., HB 6525 for Eric and Jennifer Miles, HB 6529 for J.N., and HB 6519 for the estate of Beniel Hambier, all involving settlements or compensation for injuries or wrongful death. Other measures reported favorably included CS/HB 213 on commercial squatters, CS/HB 1447 on trespass at large-scale ticketed events, CS/HB 515 updating the Uniform Commercial Code for virtual currency and related technologies, CS/HB 1007 on gift card fraud, CS/HB 1049 on protection of court officials, CS/HB 1219 on non-compete and garden leave agreements, CS/HB 399 on stolen valor in the ethics code, CS/HB 57 on xylazine regulation, HB 901 on court-appointed psychologists, and CS/HB 265 on enforcing terrorism-related judgments against frozen assets. Most of these bills had support from industry, law enforcement, or affected parties and passed with little or no opposition. The most contested measure was CS/HB 1517, which would expand Florida’s wrongful death statute to include parents of unborn children as survivors. Supporters argued it would allow families to recover damages when negligence causes the loss of a pregnancy, while opponents—including the ACLU of Florida, Planned Parenthood affiliates, reproductive rights advocates, and some committee members—warned it could be used to advance fetal personhood, chill medical care, and empower abusive partners or others to sue over abortion-related conduct. The sponsor said the bill remained within the wrongful death framework and included protections for mothers and lawful medical providers, but the committee still reported it favorably on a 14-6 vote. CS/HB 903, a corrections bill addressing inmate litigation, sentencing, execution methods, tracking devices, health services, and offender review appointments, also drew debate over a proposed tolling amendment and due process concerns; the amendment failed and the bill passed 16-5. CS/HB 57 on xylazine likewise saw debate over whether penalties should target users or traffickers, but the committee rejected a narrowing amendment and passed the bill 20-1. Several bills were amended in committee, often with technical or clarifying changes, including CS/HB 1219, HB 1351 on sexual offender and predator registration, and HB 901. Public testimony was generally supportive on the non-controversial bills, especially from law enforcement, business groups, and affected claimants. At the end of the meeting, Rep. Gottlieb offered a personal correction, acknowledging he had wrongly criticized FOP in a prior meeting after learning the organization had, in fact, contacted him. The committee then adjourned after completing the full agenda.